Crystal structure of a Chimeric Antigen Receptor (CAR) scFv domain rearrangement forming a VL-VL dimer

Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies are dependent upon designed transmembrane proteins to bind target antigens and stimulate an immune response. The success or failure of these CARs is only partially predictable, yet recent work has highlighted the importance of antigen binding scFvs driving distinct oligomerization states with varied CAR-T efficacy. Here, we sought to determine the extracellular structure of the anti-CD19 CAR 47G4-CD828Z. Unexpectedly, the resolved crystal structure revealed an IgVL homodimer bound along an inverted VL|VL interface. We found that the VL-VH linker, designed to be cleavage resistant, was cleaved, and the VH and CAR hinge domains were absent from the crystal structure lattice. Molecular Dynamics simulations revealed that the inverted VL|VL interface was more stable than the canonical VL|VL configuration. Our work substantiates the need to interrogate the scFv structure and CAR oligomerization state for optimal CAR-T design.

[1]  Devlina Chakravarty,et al.  AlphaFold2 fails to predict protein fold switching , 2022, bioRxiv.

[2]  Frank D. Teets,et al.  AlphaFold accurately predicts distinct conformations based on oligomeric state of a de novo designed protein , 2022, bioRxiv.

[3]  Brandon Yushan Feng,et al.  Benchmarking AlphaFold for protein complex modeling reveals accuracy determinants , 2021, bioRxiv.

[4]  David R. Bell,et al.  Evolution of Thyroglobulin Loop Kinetics in EpCAM , 2021, Life.

[5]  S. Ovchinnikov,et al.  ColabFold: making protein folding accessible to all , 2022, Nature Methods.

[6]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[7]  D. Dimitrov,et al.  Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22 , 2021, The Journal of biological chemistry.

[8]  Yong Gu Lee,et al.  Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells , 2021, Nature Network Boston.

[9]  J. Castro,et al.  Chimeric Antigen Receptor T Cell Therapy in Oncology - Pipeline at a glance: Analysis of the ClinicalTrials.gov database. , 2021, Critical reviews in oncology/hematology.

[10]  S. Rosenberg,et al.  Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma , 2019, Nature Medicine.

[11]  Nathan H. Roy,et al.  Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy , 2019, Blood.

[12]  C. June,et al.  Engineered T Cell Therapies from a Drug Development Viewpoint , 2019, Engineering.

[13]  Jiyao Wang,et al.  iCn3D, a web-based 3D viewer for sharing 1D/2D/3D representations of biomolecular structures , 2019, Bioinform..

[14]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[15]  X. Chen,et al.  Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. , 2017, Drugs of today.

[16]  Stuart A. Sievers,et al.  Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  N. Taylor,et al.  CAR T‐cell therapy of solid tumors , 2017, Immunology and cell biology.

[18]  K. Lindorff-Larsen,et al.  Understanding single‐pass transmembrane receptor signaling from a structural viewpoint—what are we missing? , 2016, The FEBS journal.

[19]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[20]  C. June,et al.  Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies , 2015, Immunological reviews.

[21]  I. Wilson,et al.  Malachite green mediates homodimerization of antibody VL domains to form a fluorescent ternary complex with singular symmetric interfaces. , 2013, Journal of molecular biology.

[22]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[23]  S. Rosenberg,et al.  Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.

[24]  I. Pastan,et al.  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. , 2013, Blood.

[25]  Michael J. Bevan,et al.  CD8+ T Cells: Foot Soldiers of the Immune System , 2011, Immunity.

[26]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[27]  B. Volkman,et al.  A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. , 2010, Structure.

[28]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[29]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[30]  Mitchell Ho,et al.  Identification and characterization of fully human anti-CD22 monoclonal antibodies , 2009, mAbs.

[31]  S. Rosenberg,et al.  Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.

[32]  F. Wurm,et al.  High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. , 2008, Biotechnology and bioengineering.

[33]  Brian G Fox,et al.  A combined approach to improving large-scale production of tobacco etch virus protease. , 2007, Protein expression and purification.

[34]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[35]  M. Little,et al.  Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. , 2004, Protein engineering, design & selection : PEDS.

[36]  A. Wu,et al.  The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. , 2003, Journal of molecular biology.

[37]  M. Schiffer,et al.  A domain flip as a result of a single amino-acid substitution. , 1998, Structure.

[38]  C. Jarzynski Equilibrium free-energy differences from nonequilibrium measurements: A master-equation approach , 1997, cond-mat/9707325.

[39]  A. Brünger,et al.  Comparison of crystal structures of two homologous proteins: structural origin of altered domain interactions in immunoglobulin light-chain dimers. , 1994, Biochemistry.

[40]  R. Poljak Production and structure of diabodies. , 1994, Structure.

[41]  K. D. Hardman,et al.  An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. , 1993, Protein engineering.

[42]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Chothia,et al.  Domain association in immunoglobulin molecules. The packing of variable domains. , 1985, Journal of molecular biology.

[44]  J. Novotný,et al.  Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Huber,et al.  The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution. , 1975, Biochemistry.

[46]  Serge X. Cohen,et al.  Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7 , 2008, Nature Protocols.

[47]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.